Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases

This publication has 58 references indexed in Scilit:

• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
  Neurobiology of Disease, 2000
• Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma Cells
  Biochemical and Biophysical Research Communications, 2000
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
  Nature Genetics, 1997
• Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors
  Clinical Pharmacokinetics, 1997
• HMG-CoA reductase inhibitors: role in normal and malignant cells
  Critical Reviews in Oncology/Hematology, 1996
• Importance of mevalonate‐derived products in the control of HMG‐CoA reductase activity and growth of human lung adenocarcinoma cell line a549
  International Journal of Cancer, 1993
• Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
  Science, 1993
• Regulation of the mevalonate pathway
  Nature, 1990